Breast Cancer

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.

Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.

IBTR with the 1 mm and 2 mm cutoff found rates found the margin widths were small and not clinically meaningful.

Ninety days of endocrine therapy before surgery could change patient/surgeon preference on concurrent radiation use in those with breast cancer.

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.

Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.

The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.